Intra-Cellular Therapies, Inc. Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc.

ITCI

株式のランク #1691
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
株価
$131.87
最終同期: 2025-04-02
時価総額
$12.68B
変化(1日)
0.00%
変化(1年)
0.00%
国
US
取引 Intra-Cellular Therapies, Inc. (ITCI)

カテゴリー

Healthcare
Intra-Cellular Therapies, Inc.(ITCI)の発行済株式数
December 2024 時点の発行済株式数 103.13M
Intra-Cellular Therapies, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 103.13M です。December 2023 の終わりには、同社は 95.88M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Intra-Cellular Therapies, Inc.(ITCI)の発行済株式数の履歴(2013 ~ 2026)
各年末時点の発行済株式数
年 発行済株式数 変化
2026 (TTM) 103.13M 0.00%
2024 103.13M 7.56%
2023 95.88M 1.95%
2022 94.05M 15.74%
2021 81.25M 15.47%
2020 70.36M 27.50%
2019 55.19M 0.87%
2018 54.71M 18.46%
2017 46.18M 6.80%
2016 43.24M 20.07%
2015 36.01M 25.69%
2014 28.65M 66.35%
2013 17.22M 0.00%
類似企業や競合他社の発行済株式数